Adverum Biotechnologies Stock (NASDAQ: ADVM)

Adverum Biotechnologies

ADVERUM BIOTECHNOLOGIES INC

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

wall street chart shutter2

Long Ideas

News

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

ADVM

TCBI

Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying

Image44

Intraday Update

APPN

More Than $10M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying

Biotech

Earnings

Analyst Ratings

General

MEDP

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adverum Biotechnologies (NASDAQ: ADVM) been one of those stocks this year?

Is Adverum Biotechnologies Stock Outpacing Its Medical Peers This Year?

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies Inc

Management

Press Releases

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Health Care

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Anixa Biosciences

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Elicio Therapeutics

Elutia

EXoZymes

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genelux

Immunic

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Macrogenics

Renovaro

Regulus Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Tenaya Therapeutics

Vor Biopharma

Vaxart

XBiotech

HC Wainwright & Co.

RBC Capital

Truist Securities

Chardan Capital

Oppenheimer

Comments

Adverum Biotechnologies

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga